Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UNEX-42 in Preterm Neonates at High Risk for BPD
NCT03857841Phase 1Terminated
- Sponsor
- United Therapeutics Corporation
- Start
- Oct 2019
- Primary completion
- May 2021
- Modality
- Lipid-based Nanoparticles, Cell Therapies
- Countries
- 1
01
Overview
Phase 1, randomised trial of UNEX-42 in bronchopulmonary dysplasia (BPD), sponsored by United Therapeutics Corporation. Primary endpoint: Number of Subjects With Treatment-emergent Adverse Events. Started Oct 2019; status: terminated.
02
Drugs
UNEX-42
03
Conditions
bronchopulmonary dysplasia (BPD)
Beyond the preview
Go deeper on NCT03857841.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03857841.